Voyager Therapeutics (FRA:VT6) Quality Rank


FRA:VT6 Voyager Therapeutics Inc FRA:VT6
53 GF Score
Price €3.16
GF Value €1.40
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Voyager Therapeutics Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Voyager Therapeutics Quality Rank Related Terms

FRA:VT6
53GF Score
Voyager Therapeutics Inc FRA:VT6
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Voyager Therapeutics (FRA:VT6) Overvalued in 2026?

Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued. The current stock price of €3.16 is trading 125.9% above its estimated GF Value™ of €1.40. GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:VT6:

  • Quality Rank:
  • GF Value™: €1.40 vs. price of €3.16 (125.9% above fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the FRA:VT6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Voyager Therapeutics Business Description

Other Exchanges VYGR:USAVYGR:Mexico
Address 75 Hayden Avenue, Lexington, MA, USA, 02421
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
53GF Score

Get the complete analysis for FRA:VT6

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.16
Price
€1.40
GF Value